These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 19296889)
1. Quality of life and quality of care for patients with gout. Singh JA Curr Rheumatol Rep; 2009 Apr; 11(2):154-60. PubMed ID: 19296889 [TBL] [Abstract][Full Text] [Related]
2. Quality of life and disability in patients with treatment-failure gout. Becker MA; Schumacher HR; Benjamin KL; Gorevic P; Greenwald M; Fessel J; Edwards L; Kawata AK; Frank L; Waltrip R; Maroli A; Huang B; ; Sundy JS J Rheumatol; 2009 May; 36(5):1041-8. PubMed ID: 19332629 [TBL] [Abstract][Full Text] [Related]
3. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. Keith MP; Gilliland WR Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966 [TBL] [Abstract][Full Text] [Related]
4. [Quality of treatment in gouty patients considering EULAR recommendations]. Radak-Perović M; Zlatković-Svenda M Srp Arh Celok Lek; 2012; 140(11-12):717-21. PubMed ID: 23350244 [TBL] [Abstract][Full Text] [Related]
5. Evaluation and treatment of gout as a chronic disease. Perez-Ruiz F; Herrero-Beites AM Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464 [TBL] [Abstract][Full Text] [Related]
6. Pegloticase and the patient with treatment-failure gout. Dave AJ; Kelly VM; Krishnan E Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270 [TBL] [Abstract][Full Text] [Related]
7. The current state of care in gout: Addressing the need for better understanding of an ancient disease. Zychowicz ME; Pope RS; Graser E J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636 [TBL] [Abstract][Full Text] [Related]
8. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. Hill EM; Sky K; Sit M; Collamer A; Higgs J J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090 [TBL] [Abstract][Full Text] [Related]
9. Managing gout: there's more we can do. Mead T; Arabindoo K; Smith B J Fam Pract; 2014 Dec; 63(12):707-13. PubMed ID: 25486309 [No Abstract] [Full Text] [Related]
10. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity. Wood R; Fermer S; Ramachandran S; Baumgartner S; Morlock R J Rheumatol; 2016 Oct; 43(10):1897-1903. PubMed ID: 27036386 [TBL] [Abstract][Full Text] [Related]
11. Hyperuricemia and gout: a reign of complacency. Mandell BF Cleve Clin J Med; 2002 Aug; 69(8):589-90, 592-3. PubMed ID: 12184467 [No Abstract] [Full Text] [Related]
12. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Khanna PP; Perez-Ruiz F; Maranian P; Khanna D Rheumatology (Oxford); 2011 Apr; 50(4):740-5. PubMed ID: 21147824 [TBL] [Abstract][Full Text] [Related]
13. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al. Meltzer M Arthritis Care Res (Hoboken); 2013 May; 65(5):838. PubMed ID: 23281274 [No Abstract] [Full Text] [Related]
15. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680 [TBL] [Abstract][Full Text] [Related]
16. Updates in the management of gout. Keith MP; Gilliland WR Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440 [TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to urate-lowering therapies in the Irish setting. McGowan B; Bennett K; Silke C; Whelan B Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858 [TBL] [Abstract][Full Text] [Related]
18. Opportunities for improving medication use and monitoring in gout. Singh JA; Hodges JS; Asch SM Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554 [TBL] [Abstract][Full Text] [Related]
19. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780 [TBL] [Abstract][Full Text] [Related]
20. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Beutler AM; Rull M; Schlesinger N; Baker DG; Hoffman BI; Schumacher HR Clin Exp Rheumatol; 2001; 19(5):595. PubMed ID: 11579724 [No Abstract] [Full Text] [Related] [Next] [New Search]